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Abstract
Background:  The objective of this study was to examine outcomes in patients undergoing
esophageal resection for adenocarcinoma at our institution during a 20-year period and, in
particular, to address temporal trends in long-term survival.
Methods:  Out of 470 patients who underwent esophagectomy for malignancy between
September 1985 and September 2005, a total number of 175 patients presented with esophageal
adenocarcinoma. Patients enrolled in this study included AEG (adenocarcinoma of the
esophagogastric junction) type I tumors only. Time trends were studied comparing two decades,
9/1985 to 9/1995 (DI) and 10/1995 to 9/2005 (DII).
Results: The overall survival was significantly more favourable in patients undergoing esophageal
resection for adenocarcinoma in the recent time period (DII, 10/1995 to 9/2005) as compared to
the early time period (DI, 9/1985 to 9/1995) (log rank test: p = 0.0329). Significant differences in
the recent decade were seen based on lower ASA-classifications, earlier tumor stages, and the
operative procedure with a higher frequency of transhiatal resections (p < 0.05). 30-day mortality
improved from 8.3% to 3.1% during the 20-year time-interval, thus without statistical significance.
Conclusion: Based on our experience, overall survival is improving over time for adenocarcinoma
of the esophagus. Factors that may play an important role in this trend include early diagnosis and
improved patient selection through better preoperative staging, improved surgical technique with
a tailored approach carefully evaluated by physiologic patient status, comorbidity and tumor extent.
Background
Esophageal resection is the only curative therapy for
patients with esophageal carcinoma. Although a variety of
retrospective studies have demonstrated improvements in
short-term outcomes in recent years, changes in long-term
survival over time are less well-established. Advances in
surgical planning, operative technique, and perioperative
care have resulted in improved short-term outcomes, with
experienced centers now reporting in-hospital mortality
rates of less than 5%, even with major resections [1].
Long-term survival and potential for cure following surgi-
cal resection for esophageal adenocarcinoma have been
demonstrated in numerous uncontrolled studies. As
esophageal surgery has become safer and indications
more differentiated, especially with respect to neoadju-
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vant therapy, there are increasing expectations regarding
assessment of trends in long-term patient outcomes.
Although some improvements in survival are being
reported in more recent series compared with those from
earlier decades, survival trends within a given group or
institution have not been clearly demonstrated.
The objective of this study was to examine outcomes in
patients undergoing esophageal resection for adenocarci-
noma at our institution during a 20-year period and, in
particular, to address temporal trends in long-term sur-
vival.
Methods
Out of 470 patients who underwent esophagectomy for
malignancy between September 1985 and September
2005 in the Department of General and Abdominal Sur-
gery of the Johannes Gutenberg-University Hospital of
Mainz, a total number of 175 patients presented with
esophageal adenocarcinoma. Adenocarcinoma enrolled
in this study only included AEG type I tumors [2]. Type II
(tumors of the cardia) and type III (subcardial tumors
with infiltration of the cardia and/or distal esophagus)
were strictly not taken into consideration.
For preoperative staging, EUS (endoscopic ultrasound),
CT (computed tomography) of the neck, chest and abdo-
men and PET (positron emission tomography) were rou-
tinely carried out. Thus, endoscopic ultrasound and PET
scan were not available at the initiation of the study back
in 1985.
Transhiatal esophagectomy with abdominal and posterior
mediastinal lymphadenectomy was routinely carried out
in adenocarcinoma, whereas the transthoracic procedure
with two-field lymphadenectomy was accomplished in
the presence of advanced tumor growth or extended
lymph node involvement. The transhiatal procedure was
done with an abdominal lymph node dissection (includ-
ing the paracardial nodes, the left gastric artery nodes
along with the lymph nodes of the lesser curvature of the
stomach, the celiac trunc, the common hepatic artery and
in selected cases – as macroscopic tumor involvement –
the splenic artery), as well as with an excision of the
lymph nodes extending as far as the carina of the trachea,
and to those lymph nodes which could be reached in the
lower, posterior mediastinum. The transthoracic tech-
nique, performed via a right dorso-lateral thoracotomy,
involved an abdominal (as described) and a more exten-
sive mediastinal lymphadenectomy in the sense of a two-
field dissection. The specimen here included the lower
and middle mediastinal, subcarinal, and right-sided par-
atracheal lymph nodes (en bloc dissection). Paratracheal
and bifurcal nodes were only removed on both sides in
case of clinical suspicion of bilateral involvement. The
aortopulmonary – window nodes were dissected sepa-
rately.
Neoadjuvant therapy was not administered in our
patients with adenocarcinoma.
Deaths within 30 days of operation were considered 30-
day mortality. Patient follow-up was obtained from death
certificates, office records, letter or telephone contact.
Time trends were studied comparing two decades, 9/1985
to 9/1995 (DI) and 10/1995 to 9/2005 (DII). These two
periods were chosen in order to achieve a balance of suffi-
cient sample number and adequate follow-up.
Statistical analysis
Data were collected prospectively in a specially estab-
lished database and retrospectively analyzed.
The SSPS 12.0 software package was used for statistical
data analysis (SSPS, Chicago, IL, USA: 2001). Data are
expressed as median with ranges (minimum - maximum),
or as percentages (%).
Patient demographics, operative and pathologic findings,
and the postoperative course were evaluated both by uni-
variate and multivariate models to determine the impact
on overall survival, which was calculated from the time of
esophageal resection. Survival analyses were estimated by
the Kaplan-Meier method [3]. Differences in survival were
compared using the log-rank test. Fisher's exact or the Χ-
square tests were used for univariate comparisons. Multi-
variate analysis was performed with the Cox Proportional
Hazard Model [4]. Differences were considered significant
if p < 0.05.
Results
Demographics
In the 20-year period, 175 patients with esophageal aden-
ocarcinoma underwent esophagectomy in our depart-
ment. The median age was 62.6 years (range 28.9–79.9).
There were 153 men (87.4%) and 22 women (12.6%). In
the 10-year period between 9/1985 and 9/1995, 48
(27.4%) patients were resected for adenocarcinoma com-
pared to 127 (72.6%) patients in the 10-year period
between 10/1995 and 9/2005. At the time of the last fol-
low-up in September 2006, 44/175 (25.1%) patients were
alive. Median follow-up of the survivors was 37 months
(range 6–170).
During the study period, 249 patients presented with
squamous cell carcinoma; in 32 patients, an undifferenti-
ated histologic type was found and 14 patients displayed
other malignant tumors of the esophagus.BMC Cancer 2007, 7:114 http://www.biomedcentral.com/1471-2407/7/114
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Surgical therapy
123 (70.3%) patients underwent transhiatal esophagec-
tomy and 52 (29.7%) had an abdominothoracic proce-
dure with two-field (abdominal and mediastinal)
lymphadenectomy.
Reconstruction was accomplished by pulled-up gastric
tube in 168 (96.6%) patients, by colon interposition in 4
(2.3%), whereas in 2 (1.1%) patients no primary recon-
struction was performed due to emergency resection
(tumor haemorrhage). The anatomic prevertebral esopha-
geal bed was used for the majority of these procedures (n
= 165; 95.4%). Extra-anatomic reconstruction by the ret-
rosternal route with cervical anastomosis after pull-up was
carried out in 7 (4.0%) patients only. The 30-day mortal-
ity was 4.6% (8 patients).
Long-term outcomes
Actuarial overall survival (R0-resections) was 33% at 3
years, 22.5% at 5 years, and 13.2% at 10 years, with a
median survival of 21 months (range 0–170).
Multivariate analysis of prognostic factors for overall sur-
vival (R0-resections) proved pT-category (HR:1.574;
95%CI:1.220–2.031), nodal status (HR:1.790;
95%CI:1.136–2.820) and pM-category (HR:1.806;
95%CI:1.145–2.847) as independent predictors.
Differences between time periods: 9/1985 to 9/1995 versus 
10/1995 to 9/2005
Comparisons were made in demographics, tumor charac-
teristics, and surgical treatment of the two time period
groups in order to determine potential reasons for long-
term outcome differences (Table 1). Significant differ-
Table 1: Clinicopathological features and operative course
Decade I (9/1985–9/1995) (n = 48) Decade II (10/1995–9/2005) (n = 127) p-value
age (years) 62.1 (41–78.3) 62.6 (28.9–79.9) n.s.
gender (males) 43 (89.6%) 110 (86.6%) n.s.
ASA-classification
-ASA I 0 0
-ASA II 14 (30.4%) 58 (47.9%) 0.008*
-ASA III 27 (58.7%) 61 (50.4%)
-ASA IV 5 (10.9%) 2 (1.7%)
tumor site
-middle third 8 (16.7%) 8 (6.3%) n.s.
-lower third 40 (83.3%) 118 (93.7%)
UICC-classification
-I 6 (12.8%) 18 (14.3%)
-IIA 9 (19.1%) 19 (15.1%) 0.017*
-IIB 0 24 (19%)
-III 18 (38.3%) 30 (23.8%)
-IV 14 (29.8%) 35 (27.8%)
R-classification
-R0 40 (83.3%) 115 (91.3%) n.s.
-R1 6 (12.5%) 10 (7.9%)
-R2 2 (4.2%) 1 (0.8%)
operative procedure
-transhiatal 16 (33.3%) 107 (84.3%) <0.0001*
-transthoracic 32 (66.7%) 20 (15.7%)
number of lymph nodes
-dissected 19 (0–93) 23 (3–79) n.s.
-involved 2 (0–76) 3 (0–33) n.s.
30-day mortality 4 (8.3%) 4 (3.1%) n.s.
*statistically significantBMC Cancer 2007, 7:114 http://www.biomedcentral.com/1471-2407/7/114
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ences were seen based on ASA-classification, tumor stage,
and operative procedure (p < 0.05). There was no signifi-
cant difference for age, gender, tumor site, residual tumor,
and number of dissected or involved lymph nodes
between time periods. 30-day mortality improved from
8.3% to 3.1% during the 20-year time-interval, thus with-
out statistical significance.
Differences in survival (R0-resections) between time peri-
ods are demonstrated in Figure 1. The overall survival was
significantly more favourable in patients undergoing
esophageal resection for adenocarcinoma in the recent
time period compared to the early time period (log rank
test: p = 0.0329). 3 (5)-year survival for this group
improved from 17.5% (15%) to 40% (25%) between the
two decades. Cox Proportional Hazard Model (R0-resec-
tions) for decade I revealed pN-category (HR:2.444;
95%CI:1.219–4.901) as the only independent prognostic
factor of overall survival, whereas pT-category, distant
metastases, grading, age, gender and ASA-classification
were not significant (p > 0.05) (multivariate analysis). In
contrast, decade II showed – in addition to pN-category
(HR:1.866; 95%CI:1.005–3.462) – pT-(HR:1.777;
95%CI:1.249–2.529) and pM-category (HR:1.766;
95%CI:1.017–3.067) as independent predictors of
favourable long-term survival with no significance for the
other variables mentioned above (p > 0.05) (Table 2).
Subdividing all 175 patients into two groups dichot-
omized according to median overall survival (> 17.2
months: LTS = long-term survivors versus  </= 17.2
months: STS = short-term survivors), significant differ-
ences in both decades were seen based on tumor stage
only (p = 0.004 decade I and p > 0.0001 decade II) (Table
3).
Discussion
This study, from a single tertiary-care referral center over a
20-year period, demonstrates significant developments in
esophageal surgery for adenocarcinoma with regard to
patient-related, tumor-specific and operative features and
underlines our concept of surgical approach being offered
to patients with this histologic entity.
Our data clearly show a favourable trend in improved
long-term outcome over time for adenocarcinoma of the
esophagus. Although significant advances in early detec-
tion, patient selection, operative technique and perioper-
ative management have occurred in recent years, such a
long-term trend in survival has not been well established
in the literature. Several institutions have published their
experience of improved outcome following resection of
esophageal carcinoma including patients from different
time periods [5-8]. Variability in inclusion criteria, neoad-
juvant therapy, overlap of patient populations, and differ-
ences in analytic methods between reports limit the
Comparison of two decades: Significantly better long-term  survival for Decade II (10/1995 to 9/2005) as compared to  Decade I (9/1985 to 9/1995) after curative (R0) resection for  adenocarcinoma of the esophagus Figure 1
Comparison of two decades: Significantly better long-term 
survival for Decade II (10/1995 to 9/2005) as compared to 
Decade I (9/1985 to 9/1995) after curative (R0) resection for 
adenocarcinoma of the esophagus.
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Table 2: Predictors of long-term survival: Cox Proportional Hazard Model(R0)
Decade I (9/1985–9/1995) (n = 40) Decade II (10/1995–9/2005) (n = 115)
multivariate analysis Hazard Ratio (95% CI) p-value Hazard Ratio (95% CI) p-value
pT-category 1.267 (0.793–2.024) n.s. 1.777 (1.249–2.529) 0.001*
pN-category 2.444 (1.219–4.901) 0.012* 1.866 (1.005–3.462) 0.048*
pM-category 1.544 (0.658–3.622) n.s. 1.766 (1.017–3.067) 0.043*
grading 1.017 (0.593–1.746) n.s. 1.143 (0.787–1.661) n.s.
age 1.017 (0.970–1.067) n.s. 1.002 (0.975–1.030) n.s.
ASA 0.989 (0.460–2.125) n.s. 0.993 (0.613–1.608) n.s.
gender 1.882 (0.613–5.778) n.s. 0.535 (0.235–1.217) n.s.
*statistically significantBMC Cancer 2007, 7:114 http://www.biomedcentral.com/1471-2407/7/114
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ability to draw conclusions regarding long-term outcome
trends in survival from comparisons of these studies.
A variety of possible explanations for the observed trend
in improved outcome for esophageal adenocarcinoma
can be considered. Along with the changing epidemiology
[9-12], surveillance programs for patients with Barrett's
esophagus as well as better preoperative endoscopic and
imaging studies play a critical role in improving patient
selection [13-17]. Whereas early tumors were uncommon
among the surgically treated patients with esophageal
adenocarcinoma before 1990, early Barrett's carcinoma
(pT1) now constitutes about 20% of all resected adeno-
carcinomas in our patients.
A recent report addressed an approximately 20% diagnos-
tic gain with consecutive improved patient selection
through better preoperative staging by positron emission
tomography (PET) scan in combination with high resolu-
tion multislice CT scanning [18]. Due to the high sensitiv-
ity of CT findings with regard to metastatic sites in our
patient population, preoperative PET was not character-
ized by greater accuracy of lesions previously detected by
CT and consequently did not change the indication for
esophagectomy [19]. Therefore, when determining the
impact of newer staging techniques such as PET on long-
term outcomes, carefully controlled trials should be con-
sidered.
The increasingly less aggressive surgical approach we have
undertaken at our institution when confronted with ade-
nocarcinoma of the esophagus – namely the transhiatal
approach with a reduced perioperative morbidity and
mortality as compared to transthoracic resection [20] –
may also have contributed to the observed improvement
in overall survival. Our concept of individualized surgical
treatment according to the histologic type and extent of
the disease is justified by findings derived from studies
investigating the spread of lymph nodes in cases of aden-
ocarcinoma, allowing one to conclude that the lymph
node metastases associated with distal adenocarcinomas
are initially seen to metastasize into the lymph nodes in
the vicinity of the tumor and only later into the lymph
nodes of the upper mediastinal region [21].
A recent analysis of own patients did not demonstrate a
relevant difference in survival for patients with N0 and N1
stages undergoing transhiatal or transthoracic esophagec-
tomy for adenocarcinoma [22]. It is questionable and has
statistically not proved significant in a prospective rand-
omized study by Hulscher et al. [23], if an extensive medi-
astinal lymph node dissection in addition to the clearance
Table 3: Long-term survival (LTS) versus Short-term survival (STS)
Decade I (9/1985–9/1995) (n = 48) Decade II (10/1995–9/2005) (n = 127)
LTS/STS p-value LTS/STS p-value
age (years) 64.3/60.8 n.s. 61.9/63.3 n.s.
ASA (%)
-ASA I 0 0
-ASA II 28/33.3 n.s. 49.2/46.8 n.s.
-ASA III 60/57.1 49.2/51.6
-ASA IV 12/9.5 1.7/1.6
operative approach (%)
-transhiatal 34.6/31.8 n.s. 88.7/80 n.s.
-transthoracic 65.4/68.2 11.3/20
UICC-classification (%)
-I 23.1/0 26.2/3.1
-IIA 30.8/4.8 19.7/10.8
-IIB 0 0.004* 23/15.4 <0.0001*
-III 23.1/57.1 16.4/30.8
-IV 23.1/38.1 14.8/40
R-classification (%)
-R1 84.6/81.8 n.s. 93.5/89.1 n.s.
-R2 7.7/18.2 6.5/9.4
-R3 7.7/0 0/1.6
*statistically significantBMC Cancer 2007, 7:114 http://www.biomedcentral.com/1471-2407/7/114
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of abdominal lymph nodes offers any prognostic advan-
tages in adenocarcinoma of the esophagus considering
the increased morbidity associated with the transthoracic
approach.
In the last decade, most experienced esophageal surgeons
have implemented significant changes in operative tech-
nique for esophageal resection. Innovations in surgical
technology, such as mechanical staplers and haemostatic
devices have resulted in clear improvement in short-term
outcomes. Several studies have reported trends in decreas-
ing mortality and shorter hospital stay by improved peri-
operative management as peridural anesthesia, early
extubation, and intensive physical therapy after esopha-
geal resections. Whether advances in surgical technique
and operative management contribute to improved long-
term outcome is not clear.
Neoadjuvant chemoradiotherapy followed by surgery is
being used with increasing frequency and continues to be
actively studied in the surgical management of locally
advanced esophageal cancer. Pathologic complete
responses are seen in up to 30% of patients [24]. Thus, the
beneficial effect of neoadjuvant therapy in esophageal
adenocarcinoma remains doubtable. Our own long-term
results are compared to randomized prospective trials
including patients with adenocarcinoma treated either by
chemotherapy plus surgery (CS) versus surgery alone (S)
[25,26] or chemoradiotherapy plus surgery (CRT) versus
surgery (S) [27-29] in Table 4. Only two of the listed trials
could show a survival benefit of combined preoperative
chemoradiotherapy [27] or preoperative chemotherapy
[26]. However, survival analyses did not clearly differ
between the two histologic tumor types and the single
study consisting of patients with adenocarcinoma only
[27], has largely been criticized for insufficient preopera-
tive staging procedures and a very poor outcome of the
surgery group with a 3-year-survival rate of 6%. A metaa-
nalysis by Arnott et al. of all available trials concerning
neoadjuvant radiotherapy – again without a clear differ-
entiation between adenocarcinoma and squamous cell
carcinoma – concluded that neoadjuvant radiotherapy
did not improve survival and thus was not justified [30].
According to a critical appraisal recently published by SR
DeMeester, a generic recommendation for neoadjuvant
therapy in patients with esophageal adenocarcinoma is
unwarranted, until complete pathologic response rates
improve or until those patients most likely to achieve a
complete response are accurately identified before initia-
tion of therapy [31].
Conclusion
In summary, our data provide significant developments in
esophageal surgery for adenocarcinoma over a 20-year
study period. Based on our experience, overall survival is
improving over time. Factors that may play a role in this
trend include early diagnosis and improved patient selec-
tion through better preoperative staging, improved surgi-
cal technique with a tailored approach carefully evaluated
by physiologic patient status, comorbidity and tumor
extent. Promising new horizons in the surgical treatment
of esophageal adenocarcinoma are minimal-invasive and
limited resections as well as molecularbiologic-based
treatment modalities that will have to compete with the
current achievements in the next decade.
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Table 4: Randomized prospective trials of neoadjuvant therapy plus surgery versus surgery alone for esophageal adenocarcinoma
author/year n survival: C + S survival: S p-value
Kelsen/1998 (25) 440 (54% ADC, 46% SCC) 14.9 mo 2 yr: 35% 16.1 mo 2 yr: 37% n.s.
MRC/2002 (26) 802 (66% ADC, 31% SCC) 16.8 mo 2 yr: 43% 13.3 mo 2 yr: 34% 0.004*
survival: CR + S survival: S
Walsh/1996 (27) 58 (100% ADC) 16 mo 3 yr: 32% 11 mo 3 yr: 6% 0.01*
Urba/2001 (28) 100 (75% ADC, 25% SCC) 16.9 mo 3 yr: 30% 17.9 mo 3 yr: 16% n.s.
Burmeister/2002 (29) 256 (61.7% ADC, 37.1% SCC) 21.7 mo 3 yr: 38% 18.5 mo 3 yr: 31% n.s.
Junginger 2006 175 ADC 17.2 mo 3 yr: 33%
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